The IFM team sets up a three-peat as Novartis funds cGAS/STING program — with $840M option to buy
First there was Bristol-Myers Squibb’s $2.3 billion-plus deal with IFM — $300 million up front — to grab preclinical small molecules to activate NLRP3 and STING …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
